The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India
The industry is taking the lead in using the devices and a wider business use is expected soon
Only 2,000 of the 10,500 manufacturing units in the country have the World Health Organization's GMP certification
Torrent had reached out to several private equity (PE) funds, including Bain Capital to secure the necessary funds to buyout the promoter family of Cipla
The total income for Q1FY24 came in at Rs 486.9 crore, compared to Rs 430.6 crore year-on-year
It is the fastest growing segment in IPM with a 25% CAGR
As compared to Rs 959.2 crore in the quarter that ended on March 31, the net profit was up 46%
Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers
Large manufacturers are leveraging new-age technologies and advanced analytics to improve productivity and reduce deviations in production processes
72 pharmaceutical companies have brands that fall under banned FDCs, says one expert
As of now the labels on medicines only declare active substances, which are added to the formulation
Diazepam Rectal Gel had estimated annual sales of $34 million in the US
Mankind Pharma IPO listing date: The IPO is likely to list on NSE and BSE on May 8
Senior government sources indicated that the government is in favour of e-prescription, but wants to tread cautiously when it comes to e-pharmacies, given the wider implications
In a major crackdown against the manufacture of substandard drugs, central and state regulators conducted joint inspections at 76 pharma companies and cancelled the licences of 18 of them for producing spurious and adulterated drugs, official sources said on Tuesday. The inspections were carried out across 20 states and Union territories in the past 15 days, they said. A source said that the action has been taken against 76 companies in the first phase of a special drive against the manufacture of substandard drugs. "Licences of 18 pharma companies have been cancelled for manufacturing spurious and adulterated drugs and for violating GMP (good manufacturing practice).... Besides, 26 firms have been given show-cause notices," an official source said. The sources said that as part of the special drive, the regulators have identified 203 firms. A majority of the companies are from Himachal Pradesh (70), followed by Uttarakhand (45) and Madhya Pradesh (23). Recently, questions have b
A mission will be launched to eliminate sickle cell anaemia in the country by 2047, says Finance Minister
Market share gains in the Indian market and margin expansion are other positives
Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF
Glenmark Pharmaceuticals Ltd on Tuesday said its US arm has launched its generic version of diuretic Bumetanide injection. In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials. These are the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC, it added. The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan said. The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.
Drug firm Gland Pharma on Friday said it has inked a pact with FPCI Sino French Midcap Fund to acquire 100 per cent stake in Europe-based Cenexi Group. Gland Pharma International PTE, a Singapore-based wholly owned subsidiary of the company, has entered into a share purchase agreement with FPCI Sino French Midcap Fund to fully acquire stake in Cenexi pursuant to the terms of the put option agreement inked in November last year. On November 29, 2022, the Hyderabad-based drug contract development and manufacturing company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to EUR 120 million (around Rs 1,015 crore), marking its foray into the international markets. Under the put option, an entity gets the right not obligation to sell a specified amount or stake at a predetermined price. Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical ...